Bronchiolitis Obliterans Syndrome Market Size in the 7MM is expected to grow by 2032, estimated DelveInsight

DelveInsight’s “Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Bronchiolitis Obliterans Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Bronchiolitis Obliterans Syndrome Market is an evolving segment of the global healthcare landscape, driven by the increasing Bronchiolitis Obliterans Syndrome prevalence of the disorder and the continuous development of innovative treatment options. The Bronchiolitis Obliterans Syndrome market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Bronchiolitis Obliterans Syndrome Market with DelveInsight’s In-Depth Report @ Bronchiolitis Obliterans Syndrome Market Size

Key Takeaways from the Bronchiolitis Obliterans Syndrome Market Report

• In November 2024:- Incyte Biosciences Japan GK- A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After at Least 2 Lines of Systemic Therapy. This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).
• In November 2024:- Incyte Corporation- This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
• In November 2024: Deciphera Pharmaceuticals, LLC- The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
• According to DelveInsight, in 2022, the total diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) were approximately 17,000 in the United States, which is expected to grow during the study period, i.e., 2019–2032.
• The highest number of total diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) was observed in Germany among EU4 and the UK, with approximately 3,900 cases in 2022 which are expected to grow during the study period, i.e., 2019–2032.
• In 2022, the total diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) were approximately 2,400 cases in Japan, which is expected to grow during the study period, i.e., 2019–2032.
• The leading Bronchiolitis Obliterans Syndrome Companies such as Zambon Pharma, GlaxoSmithKline, Incyte Corporation, Mereo Biopharma, Genentech, and others.
• Promising Bronchiolitis Obliterans Syndrome Therapies such as ARINA-1, Belumosudil, Fluticasone, Azithromycin, LAM-001, Ruxolitinib, and others.

Stay ahead in the Bronchiolitis Obliterans Syndrome Therapeutics Market with DelveInsight’s Strategic Report @ Bronchiolitis Obliterans Syndrome Market Outlook

Bronchiolitis Obliterans Syndrome Epidemiology Segmentation in the 7MM

• Total Bronchiolitis Obliterans Syndrome Diagnosed Prevalent Cases
• Bronchiolitis Obliterans Syndrome Grade-specific Cases
• Total Bronchiolitis Obliterans Syndrome Treated Cases

Download the report to understand which factors are driving Bronchiolitis Obliterans Syndrome epidemiology trends @ Bronchiolitis Obliterans Syndrome Prevalence

Bronchiolitis Obliterans Syndrome Emerging Drugs Profile

• Liposomal Cyclosporine A: Zambon Pharma

Liposomal Cyclosporine A for inhalation (L-CsA-i) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. L-CsA-i is administered via a drug-specific investigational eFlow technology nebulizer system. The investigational drug-device combination is designed to deliver L-CsA-i to the site of disease in the lung. L-CsA-i is currently being evaluated to treat Bronchiolitis Obliterans Syndrome (BOS) in patients aged 6 years and older in the BOSTON clinical development program, which comprises five ongoing or planned trials. The drug has been awarded Fast Track designation from the US FDA for the treatment of Bronchiolitis Obliterans Syndrome (BOS). As currently, no approved treatment is available for patients with Bronchiolitis Obliterans Syndrome (BOS), a rare, devastating disease that displays a huge unmet medical need. L-CsA-I can potentially address the existing unmet need of Bronchiolitis Obliterans Syndrome (BOS) and fetch maximum revenue.

• MPH966 (alvelestat): Mereo Biopharma

MPH-966 (formerly AZD 9668) is a novel, oral-small molecule that inhibits neutrophil elastase (NE). This neutrophil protease is a key enzyme in destroying lung tissues. Alvelestat is currently being investigated in Phase I/II study in adult patients who have undergone hematopoietic stem cell transplantation and were diagnosed with Bronchiolitis Obliterans Syndrome (BOS). Interim results of Phase I/II clinical study of alvelestat have shown efficacious in the treatment of Bronchiolitis Obliterans Syndrome (BOS). Alvelestat is a disease-modifying agent and can be a blockbuster in treating Bronchiolitis Obliterans Syndrome (BOS).

Bronchiolitis Obliterans Syndrome Market Outlook

Treatment of Bronchiolitis Obliterans Syndrome (BOS) after lung transplant/allo-HSCT involves augmenting immunosuppression as a form of chronic rejection. Hence, increasing or adding immunosuppressive agents like tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone are used to treat Bronchiolitis Obliterans Syndrome (BOS) after transplant. Azithromycin has been demonstrated to improve lung function and lower the incidence of Bronchiolitis Obliterans Syndrome (BOS). The reduction in lung function in Bronchiolitis Obliterans Syndrome (BOS) post-HSCT can be slowed down by combining inhaled fluticasone, oral montelukast, and Zithromax.

Get In-Depth Knowledge on Bronchiolitis Obliterans Syndrome Market Trends and Forecasts with DelveInsight @ Bronchiolitis Obliterans Syndrome Treatment Market

Scope of the Bronchiolitis Obliterans Syndrome Market Report

• Coverage- 7MM
• Bronchiolitis Obliterans Syndrome Companies- Zambon Pharma, GlaxoSmithKline, Incyte Corporation, Mereo Biopharma, Genentech, and others.
• Bronchiolitis Obliterans Syndrome Therapies- ARINA-1, Belumosudil, Fluticasone, Azithromycin, LAM-001, Ruxolitinib, and others.
• Bronchiolitis Obliterans Syndrome Market Dynamics: Bronchiolitis Obliterans Syndrome Market Drivers and Barriers
• Bronchiolitis Obliterans Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight’s Comprehensive Bronchiolitis Obliterans Syndrome Market Report @ Bronchiolitis Obliterans Syndrome Market Drivers and Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Bronchiolitis Obliterans Syndrome (BOS) Market Overview at a Glance

4. Executive Summary of Bronchiolitis Obliterans Syndrome (BOS)

5. Bronchiolitis Obliterans Syndrome Epidemiology and Market Methodology

6. Disease Background and Overview

7. Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population

8. Bronchiolitis Obliterans Syndrome Patient Journey

9. Key Endpoints in Bronchiolitis Obliterans Syndrome (BOS) Clinical Trials

10. Emerging Bronchiolitis Obliterans Syndrome Therapies

11. Bronchiolitis Obliterans Syndrome: 7 Major Market Analysis

12. Bronchiolitis Obliterans Syndrome Market Access and Reimbursement

13. Bronchiolitis Obliterans Syndrome KOL Views

14. SWOT Analysis

15. Bronchiolitis Obliterans Syndrome Unmet Needs

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/